Scarica l'app Stockscreener
28.14
2.26%
-0.65
Pre-mercato:
28.18
0.04
+0.14%
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe - TradingView
Agios Pharmaceuticals Gains EU Approval for PYRUKYND in Adult Thalassaemia - World Business Outlook
Agios, Partner von Avanzanite Bioscience, gibt die Zulassung von PYRUKYND® (Mitapivat) in der Europäischen Union für Erwachsene mit Thalassämie bekannt - The Joplin Globe
Agios Pharmaceuticals (AGIO) Secures EU Approval for PYRUKYND - GuruFocus
EU approves mitapivat for thalassaemia treatment in adults - Investing.com UK
EU approves mitapivat for thalassaemia treatment in adults By Investing.com - Investing.com Nigeria
Avanzanite Bioscience's partner Agios announces Pyrukynd® (mitapivat) approval in EU - marketscreener.com
Agios Gets EU Approval for Pyrukynd in Thalassemia - Moomoo
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia - standard-journal.com
New oral thalassemia drug PYRUKYND approved for adults in EU - Stock Titan
Agios' Pyrukynd® (mitapivat) approved in the European Union for adults with thalassemia - marketscreener.com
Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia - The Manila Times
Agios Pharmaceuticals Receives EU Approval for PYRUKYND® as First Medicine for Thalassemia Treatment in Adults - Quiver Quantitative
(AGIO) Volatility Zones as Tactical Triggers - Stock Traders Daily
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances - Yahoo Finance
Agios Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
AGIO beats on Q1 earnings & sales, stock up 13% on new drug momentum - MSN
Why is Agios Pharmaceuticals stock surging Tuesday afternoon? - MSN
Agios plans Q2 sNDA filing for mitapivat in sickle cell disease while citing >$10B 2030 market opportunity - MSN
How Investors Are Reacting To Agios Pharmaceuticals (AGIO) FDA Bid For Mitapivat In Sickle Cell Disease - Sahm
Armistice Capital (NASDAQ: AGIO) holds 2.716M shares, 4.57% stake - Stock Titan
Assessing Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Volatility - Yahoo Finance
How Agios’ Mitapivat sNDA And New SCD Trial Design At Agios Pharmaceuticals (AGIO) Has Changed Its Investment Story - Yahoo Finance
Developer seeking FDA’s accelerated approval for mitapivat for SCD - Sickle Cell Disease News
TradingKey - TradingKey
Agios sNDA And EHA Plenary Put Mitapivat At Center Of Valuation - Yahoo Finance
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease - The Globe and Mail
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $41 - Moomoo
Agios Pharmaceuticals (AGIO) Showcases Promising Mitapivat Data at EHA 2026 - GuruFocus
Agios submits application for mitapivat in sickle cell disease - Investing.com UK
Agios presents mitapivat data at European hematology congress By Investing.com - Investing.com Australia
Agios submits application for mitapivat in sickle cell disease By Investing.com - Investing.com Australia
Agios presents mitapivat data at European hematology congress - Investing.com
Agios Pharmaceuticals to Present RISE UP Phase 3 Trial Results of Mitapivat in Sickle Cell Disease at EHA 2026 Plenary Session - Quiver Quantitative
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease - The Manila Times
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias - The Manila Times
New pill for sickle cell moves to FDA review, aims to cut transfusions - Stock Titan
Oral drug lifts hemoglobin in sickle cell and thalassemia trial - Stock Titan
Price-Driven Insight from (AGIO) for Rule-Based Strategy - Stock Traders Daily
47,414 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by State of New Jersey Common Pension Fund D - MarketBeat
Number of shareholders of Agios Pharmaceuticals, Inc. – TRADEGATE:8AP - TradingView
Lynx1 (AGIO) discloses 5.1% stake — 3.01M shares reported - Stock Titan
Need To Know: Analysts Are Much More Bullish On Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenues - 富途牛牛
Agios Pharmaceuticals Stock Rises 11.2% on Strong Q1 2026 Aqvesme Launch and Pipeline Progress - IndexBox
Agios Pharmaceuticals (AGIO) Is Up 11.2% After Rare Disease Launch And FDA Acceleration NewsHas The Bull Case Changed? - Sahm
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026) - Yahoo Finance
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):